Chromoblastomycosis: An Update On Pathogenesis, Clinical Features, And Diagnosis
Keywords:
Chromoblastomycosis, dematiaceous fungi, Fonsecaea pedrosoi, Cladophialophora carrionii, skin lesions, fungal infectionsAbstract
Chromoblastomycosis is a chronic, subcutaneous fungal infection primarily caused by dematiaceous fungi, such as Fonsecaea pedrosoi and Cladophialophora carrionii. It presents as verrucous skin lesions and predominantly affects individuals in tropical and subtropical regions, particularly farmers and laborers. The disease progresses slowly, often leading to significant morbidity due to its complications, including secondary infections and potential squamous cell carcinoma. Diagnosis is challenging and typically involves direct microscopy, histopathology, culture techniques, and emerging molecular methods. Recent advancements in diagnostic tools, such as next-generation sequencing and MALDI-TOF MS, offer promising avenues for improving early detection and species identification. Despite these advances, gaps remain in our understanding of the fungal pathogenesis, immune response, and host-pathogen interaction. This review discusses the etiology, pathogenesis, clinical features, diagnostic methods, and recent advances in the management of chromoblastomycosis. The need for further research, novel diagnostic tools, and global surveillance systems to enhance patient outcomes is emphasized.
References
1. Queiroz-Telles F, de Hoog S, Santos DWCL, Salgado CG, Vicente VA, Bonifaz A, et al. Chromoblastomycosis. Clin Microbiol Rev. 2017;30(1):233–76.
2. Savioli L, Crompton DWT, Daumerie D. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected tropical diseases. Vol. 2. World Health Organization; 2013.
3. Jabir M, Choolayil AC. Neglected Tropical Diseases: A Brief Introduction to the Global Scenario. In: Social Work with Populations Vulnerable to Neglected Tropical Diseases: Evidence and Insights from India. Springer; 2024. p. 1–17.
4. Organization WH. Control of Neglected Tropical Diseases: Chromoblastomycosis and Other Deep Mycoses. 2017.
5. Santos DWCL, de Azevedo C de MP e S, Vicente VA, Queiroz-Telles F, Rodrigues AM, de Hoog GS, et al. The global burden of chromoblastomycosis. PLoS Negl Trop Dis. 2021;15(8):e0009611.
6. Belda Jr W, Casolato ATS, Luppi JB, Passero LFD. Managing chromoblastomycosis with acitretin plus imiquimod: a case report on the improvement of cutaneous lesions and reduction of the treatment time. J Dermatol. 2021;48(10):1612–5.
7. Martínez RL, Tovar LJM. Chromoblastomycosis. Clin Dermatol. 2007;25(2):188–94.
8. Passero LFD, Cavallone IN, Belda Jr W. Reviewing the Etiologic Agents, Microbe‐Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis. J Immunol Res. 2021;2021(1):9742832.
9. Brito AC de, Bittencourt M de JS. Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update. An Bras Dermatol. 2018;93:495–506.
10. Santos DWCL, Vicente VA, Weiss VA, de Hoog GS, Gomes RR, Batista EMM, et al. Chromoblastomycosis in an endemic area of Brazil: a clinical-epidemiological analysis and a worldwide haplotype network. J Fungi. 2020;6(4):204.
11. Hay R, Denning DW, Bonifaz A, Queiroz-Telles F, Beer K, Bustamante B, et al. The diagnosis of fungal neglected tropical diseases (fungal NTDs) and the role of investigation and laboratory tests: an expert consensus report. Trop Med Infect Dis. 2019;4(4):122.
12. Hasanjani Roshan MR, Shafigh E, Amanlo M, Sefidgar AA, Shidfar MR. The first case report of chromoblastomycosis in Mazandaran. J Maz Univ Med Sci. 2001;11(30):74–80.
13. Santos ALS, Palmeira VF, Rozental S, Kneipp LF, Nimrichter L, Alviano DS, et al. Biology and pathogenesis of Fonsecaea pedrosoi, the major etiologic agent of chromoblastomycosis. FEMS Microbiol Rev. 2007;31(5):570–91.
14. Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009;47(1):3–15.
15. Ezemba Chinyere C, Anyaogu Ebuka V, Etikudike Victor O, Osuala Oluchi J, Ezemba AS, Madukwe Chiamaka J. Pathogenesis and Immunology of Chromoblastomycosis: A review. J Adv Microbiol Res. 2020;1(2):61–6.
16. Queiróz AJR, Pereira Domingos F, Antônio JR. Chromoblastomycosis: clinical experience and review of literature. Int J Dermatol. 2018;57(11):1351–5.
17. Lu S, Lu C, Zhang J, Hu Y, Li X, Xi L. Chromoblastomycosis in Mainland China: a systematic review on clinical characteristics. Mycopathologia. 2013;175:489–95.
18. Damayanti N, Noor L, Purwanto H, Siswati A. Diagnosis and therapy of chromoblastomycosis. J Pakistan Assoc Dermatologists. 2022;32(2):443–8.
19. Minotto R, Bernardi CDV, Mallmann LF, Edelweiss MIA, Scroferneker ML. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol. 2001;44(4):585–92.
20. Silva JP, de Souza W, Rozental S. Chromoblastomycosis: a retrospective study of 325 cases on Amazonic Region (Brazil). Mycopathologia. 1998;143:171–5.
21. Maubon D, Garnaud C, Ramarozatovo LS, Fahafahantsoa RR, Cornet M, Rasamoelina T. Molecular diagnosis of two major implantation mycoses: chromoblastomycosis and sporotrichosis. J Fungi. 2022;8(4):382.
22. Zaias N, Rebell G. A simple and accurate diagnostic method in chromoblastomycosis. Arch Dermatol. 1973;108(4):545–6.
23. Queiroz-Telles F, de CL Santos DW. Challenges in the therapy of chromoblastomycosis. Mycopathologia. 2013;175:477–88.
24. Breda LCD, Menezes IG, Paulo LNM, de Almeida SR. Immune sensing and potential immunotherapeutic approaches to control chromoblastomycosis. J Fungi. 2020;7(1):3.
25. Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. Curr Opin Infect Dis. 2006;19(2):148–52.
26. Walsh TJ. Invasive fungal infections: problems and challenges for developing new antifungal compounds. In: Emerging Targets in Antibacterial and Antifungal Chemotherapy. Springer; 1992. p. 349–73.
27. Sousa GSM, De Oliveira RS, De Souza AB, Monteiro RC, Santo EPTE, Franco Filho LC, et al. Identification of Chromoblastomycosis and Phaeohyphomycosis Agents through ITS-RFLP. J Fungi. 2024;10(2):159.
28. Hoffmann C de C, Danucalov IP, Purim KSM, Queiroz-Telles F. Infections caused by dematiaceous fungi and their anatomoclinical correlations. An Bras Dermatol. 2011;86:138–41.
29. Moehling TJ, Choi G, Dugan LC, Salit M, Meagher RJ. LAMP diagnostics at the point-of-care: emerging trends and perspectives for the developer community. Expert Rev Mol Diagn. 2021;21(1):43–61.
